Cited by 58Cancer-related Molecular PathwaysCell death mechanisms and regulationPI3K/AKT/mTOR signaling in cancer

The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival

Open access
Valentin-Vega, Y A, Okano, H, Lozano, G·2008·Cell Death & Differentiation

Abstract

Mdm2 is the major inhibitor of the p53 tumor suppressor. Loss of Mdm2 in mice or in specific tissues of the mouse always yields p53-dependent lethal phenotypes. However, the role of Mdm2 in tissues with high turnover capacity is unknown. We have engineered mice lacking Mdm2 in the intestinal epithelium using the Cre/LoxP system. Loss of Mdm2 (Mdm2(intDelta)) results in viable animals, but neonates display multiple intestinal abnormalities such as hyperplasia, enterocyte vacuolization, and inflammation. These defects correlate with a drastic increase in p53-dependent apoptosis in highly proliferative and differentiated cells. Unexpectedly, the observed phenotypes disappear with age. The tissue selects against Mdm2-null cells and increases its proliferative capacity. Additionally, the intestinal stem and progenitor cell populations are enriched leading to an increase in crypt fission events. Enhanced proliferation is achieved by activation of the canonical Wnt and EGFR-mediated Ras/MAPK pathways. While Mdm2 is a critical inhibitor of p53 in the intestinal epithelium, the tissue employs a series of processes that compensate for cell death.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/cdd.2008.109

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In smooth muscle cells, loss of Mdmx has no phenotype.

    “However, in other cases, such as smooth muscle cells, loss of Mdmx has no phenotype.”

    From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [38]

  • Mdm2 and Mdmx contribute to p53 regulation to different extents in different tissues in vivo.

    “Mdm2 and Mdmx seem to contribute to p53 regulation to different extents in different tissues in vivo (Table 1; [32–40]).”

    From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [38]

  • In some tissues and cell types, such as the central nervous system and proliferative intestinal cells, there is a requirement for both Mdm2 and Mdmx.

    “Clearly in some tissues and cell types [such as the central nervous system (CNS) and proliferative intestinal cells], there is a requirement for both Mdm2 and Mdmx.”

    From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [38]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Valentin-Vega, Y. A., Okano, H., & Lozano, G.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Keio University (JP)
Corresponding author
Lozano, G
Venue
Cell Death & Differentiation
Published
2008-07-18
Volume
15
Issue
11
Pages
1772-1781
ISSN
  • 1350-9047 (ISSN-L)
  • 1476-5403
OpenAlex
W2061031835
Cited by
58
References
42
Citations by year
2025: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 6 · 2016: 2 · 2015: 1 · 2014: 4 · 2013: 4 · 2012: 8
FWCI
3.88
Type
journal article
Language
en
Open access
Locations
  • Cell Death and Differentiation (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (CA-16 672, CA47296)
  • National Cancer Institute (CA-16672, CA47296, R01CA047296, P30CA016672)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
MDM2, p53, intestinal epithelium, p53-dependent apoptosis, intestinal hyperplasia, intestinal inflammation, intestinal stem cells, crypt fission, Wnt signaling, EGFR, RAS/MAPK pathway, cell proliferation, tissue homeostasis
MeSH terms
Animals, Cell Differentiation, DNA, Epithelial Cells, Intestinal Mucosa, Survival Analysis, Tumor Suppressor Protein p53, Cell Death, ras Proteins, MAP Kinase Signaling System, Cell Proliferation, Wnt Proteins, Mice, Proto-Oncogene Proteins c-mdm2, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review